Rapid PSA rise may point to high risk of prostate cancer death

Men whose PSA level increases by more than 2.0 ng/mL during the year prior to a prostate cancer diagnosis may have a relatively high risk of future cancer death even if they undergo radical prostatectomy, according to a recent report in the New England Journal of Medicine (2004; 351:125-35).

Related Videos

Related Content

Advertisement

March 13th 2025

Expanded Access Program for recombinant BCG launches at first US site

Hannah Clarke

There are also 60 sites in the process of launching the EAP.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 12th 2025

House passes bill that includes 57% budget cut to medical research programs

Hannah Clarke

This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 11th 2025

Phase 3 trial launches ArteraAI Prostate Test for treatment selection

Hannah Clarke

The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.

March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.

Related Content

Advertisement

March 13th 2025

Expanded Access Program for recombinant BCG launches at first US site

Hannah Clarke

There are also 60 sites in the process of launching the EAP.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 12th 2025

House passes bill that includes 57% budget cut to medical research programs

Hannah Clarke

This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.

February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

March 11th 2025

Phase 3 trial launches ArteraAI Prostate Test for treatment selection

Hannah Clarke

The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.

March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke

"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.